LBLTF (Lattice Biologics) Total Inventories: $0.00 Mil (As of Jun. 2021)


What is Lattice Biologics Total Inventories?

Lattice Biologics LBLTF -99.00% Total Inventories is $0.00 Mil as of Jun. 2021.

Lattice Biologics's total inventories for the quarter that ended in Jun. 2021 was $0.00 Mil. Lattice Biologics's average total inventories from the quarter that ended in Mar. 2021 to the quarter that ended in Jun. 2021 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Lattice Biologics's Net-Net Working Capital per share for the quarter that ended in Jun. 2021 was $-0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lattice Biologics  (OTCPK:LBLTF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Lattice Biologics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2021 is

Net-Net Working Capital Per Share (Q: Jun. 2021 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0+0.75 * 0+0.5 * 0-0.506
-0-0)/128.218
=-0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lattice Biologics's Days Inventory for the three months ended in Jun. 2021 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2021 )/Cost of Goods Sold (Q: Jun. 2021 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lattice Biologics's Inventory Turnover for the quarter that ended in Jun. 2021 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2021 ) / Average Total Inventories (Q: Jun. 2021 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lattice Biologics's Inventory to Revenue for the quarter that ended in Jun. 2021 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2021 ) / Revenue (Q: Jun. 2021 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Lattice Biologics Total Inventories Related Terms

Lattice Biologics Total Inventories Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Total Inventories Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 1.85 1.48 0.70 0.52

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.52 0.58 0.00 0.00

Lattice Biologics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
Lattice Biologics (LBLTF) has a Total Inventories of $0.00 Mil as of Jun. 2021. The total amount of inventory as recorded on a company's balance sheet. View historical data for Lattice Biologics and its competitors.
Is Lattice Biologics' Total Inventories too high?
Lattice Biologics' current Total Inventories is $0.00 Mil.
How does Lattice Biologics' Total Inventories compare to ABT and MDT?
Lattice Biologics' Total Inventories of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Lattice Biologics and its competitors. Lattice Biologics's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Total Inventories is $0.00 Mil as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.